NAME: Dr. Saidu Sulaiman Kamara PhD
COMPANY: Higher Education
PROFESSION: Lecturer/ Research Scientist
CATEGORIES NOMINATED: Outstanding Achievement in Health
CITY: Wenzhou City, Zhejiang Province
COUNTRY BASE: China
NATIONALITY: Sierra Leonean
INSTAGRAM: Nil
LinkedIn: Saidu S. Kamara
Academic Achievement:
- Zhejiang Government Scholarship winner (2021)
- Zhejiang Government Scholarship winner (2020)
- Wenzhou Medical University MD-PHD scholarship winner (2016-2021).
- Chinese government scholarship winner (2009-2015).
International Scientific Publications:
- EBV LMP1-C binding affibody molecule downregulates MEK/ERK p90RSK pathway and inhibits the proliferation of nasopharyngeal carcinoma cells in mouse tumor xenograft models [Switzerland, 2023].
- Novel EBV LMP1 C‑terminal domain binding affibody molecules as potential agents for in vivo molecular imaging diagnosis of nasopharyngeal carcinoma [Germany, 2021].
- Novel affibody molecules targeting the HPV E6 oncoprotein inhibited the proliferation of cervical cancer cells [Switzerland, 2021].
- Generation of novel affibody molecules targeting the EBV LMP2A N-terminal domain with inhibiting effects on the proliferation of NPC cells
[England,2020].
- Novel EBV LMP-2-affibody and affitoxin in molecular imaging and targeted therapy of nasopharyngeal carcinoma [USA, 2020].
- Novel Affibody Molecules Specifically Bind to SARS-CoV-2 Spike Protein and Efficiently Neutralize Delta and Omicron Variant [USA, 2023]